PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial
Phase: PHASE3 | Sponsor: Bruyère Health Research Institute. | Compound: Psilocybin
- Status
- recruiting
- Institution
- Bruyère Health Research Institute.
- Start date
- 2025-08-01
- End date
- 2027-09-01
- Registry ID
- NCT07063862
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.